Washington, D.C. (September 27, 2022) – The Centers for Medicare and Medicaid Services (CMS) has announced it plans to reduce premiums for Medicare Part B enrollees. Following the announcement, George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s, issued the following statement regarding the premium decrease and CMS’ treatment of Alzheimer’s patients:

“The decision to reduce Medicare premiums is the one thing CMS has done this year to help people with Alzheimer’s. The Alzheimer’s community will not soon forget how just months ago CMS blamed Alzheimer’s patients for its planned historic premium increase, pointing to the cost of the only disease-modifying drug on the market. Shortly after announcing the increase, CMS then decided it would not cover that drug after all, or any other in its class. As more treatments move through the pipeline, it is incumbent on CMS to stop discriminating against Alzheimer’s patients and do what it has always done until now: cover all FDA-approved drugs regardless of cost. It’s not too late for CMS to do the right thing by the six million Americans living with Alzheimer’s.”

About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.